Mark Mayeda

14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma

Cheng‐Han Lee, Wen‐Bin Ou, Adrián Mariño‐Enríquez et al. · Proceedings of the National Academy of Sciences · 2012 · 256 citations · Full text

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Ellen Weisberg, Hwan Geun Choi, Arghya Ray et al. · Blood · 2010 · 64 citations · Full text

The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

Tomoko Smyth, Thomas Van Looy, Jayne Curry et al. · Molecular Cancer Therapeutics · 2012 · 59 citations

<i>CDKN2A</i>/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans

Grant Eilers, Jeffrey T. Czaplinski, Mark Mayeda et al. · Molecular Cancer Therapeutics · 2015 · 51 citations · Full text

Imatinib-resistant Dermatofibrosarcoma Protuberans, Dfsp Progression, Dfsp Progress +15

Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors

Adrián Mariño‐Enríquez, W-B Ou, Glenn S. Cowley et al. · Oncogene · 2013 · 29 citations · Full text

Crucial Hsp90-cofactor, Functional Genomics, Oncogenic Agent +10